Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab
复制标题
DOI：
10.1200/jco.2006.08.8005
复制
发表时间：
2007-06-01
影响因子：
45.3
通讯作者：
Bonner, James A.
中科院分区：
文献类型：
--
作者：
Curran, Desmond;Giralt, Jordi;Bonner, James A.
PurposeIn这个随机的，III期研究，生活质量（QoL）进行了评估，在局部晚期鳞状细胞癌的头部和颈部（SCCHN）后，单独或与cetuximab.Patients和MethodsPatients与III或IV期非转移性和可测量的鳞状细胞癌的口咽部，下咽部，或喉有资格。使用欧洲癌症研究和治疗组织生活质量问卷C30评估QoL（EORTC QLQ-C30）和EORTC QLQ头颈癌特异性模块在基线、第4周以及基线后第4、8和12个月。结果在这项研究中，是在局部晚期SCCHN患者群体中进行的最大规模研究之一，424例患者接受单纯放疗（213例患者）或放疗加西妥昔单抗（211例患者）。与单纯放疗相比，放疗/西妥昔单抗显著改善了局部控制（P = 0.005）和总生存率（P = 0.03），而没有显著增加放疗相关的不良事件。当前分析的重点是西妥昔单抗对QoL的影响。两组完成QoL问卷的依从性均较高。QoL在治疗期间恶化，在停止治疗后改善，在12个月时达到基线水平。治疗组之间的QoL评分无显著差异。这在总体健康状况/QoL、社会功能、社会饮食和社会接触方面尤其明显。治疗前的全球健康状况/生活质量被确定为一个重要的预后变量在这些patients.ConclusionThe除了西妥昔单抗放疗显着改善局部区域控制和增加总生存率没有不利影响生活质量。
PurposeIn this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab.Patients and MethodsPatients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EORTC QLQ Head and Neck Cancer-Specific Module at baseline, week 4, and at months 4, 8, and 12 postbaseline.ResultsIn this study, one of the largest conducted in a population Of patients with locoregionally advanced SCCHN, 424 patients received radiotherapy alone (213 patients) or radiotherapy plus cetuximab (211 patients). Badiotherapy/cetuximab significantly improved locoregional control (P =.005) and overall survival (P =.03) compared with radiotherapy alone, without significantly increasing radiotherapy-associated adverse events. The current analysis focused on the impact of cetuximab on the QoL. Compliance with completion of QoL questionnaires was high in both arms. QoL worsened during treatment and improved after cessation of treatment, reaching baseline levels at 12 months. There were no significant differences in QoL scores between the treatment arms. This was particularly notable for global health status/QoL, social functioning, social eating, and social contact. Pretreatment global health status/QoL was identified as a significant prognostic variable in these patients.ConclusionThe addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL.